<div class="table-responsive">
    <table class="table table-striped table-hover">
        <thead>
            <tr>
                
                <th scope="col">
                    <a href="?cresstrial=12359&amp;modal=1&amp;valnames=arms&amp;order=created_at">Created at</a>
                </th>
                <th scope="col">Source</th>
                
                <th scope="col">Raw Value</th>
                <th scope="col">Validated value</th>
            </tr>
        </thead>
        <tbody>
            
            <tr class="histvalue-row" histvalueid="418507" class="table-">
                
                <td>July 7, 2022, 1:30 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Injections; Intramuscular;SOBERANA;Group 1 (experimental) FINLAY-FR-1: 50 \u00b5g RBD + 20 \u00b5g EMV / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.Group 2 (experimental) FINLAY-FR-2: 25 \u00b5g of RBD-TT / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 1 (experimental) FINLAY-FR-1: 50 \u00b5g RBD + 20 \u00b5g EMV / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 2 (experimental) FINLAY-FR-2: 25 \u00b5g of RBD-TT / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;50 \u00b5g, 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g &quot;, &quot;treatment_id&quot;: 514, &quot;treatment_name&quot;: &quot;Finlay-fr-1 anti-sars-cov-2 vaccine&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;25 \u00b5g; 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g&quot;, &quot;treatment_id&quot;: 515, &quot;treatment_name&quot;: &quot;Finlay-fr-2 anti-sars-cov-2 vaccine&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="415211" class="table-">
                
                <td>June 23, 2022, 2 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 1 (experimental) FINLAY-FR-1: 50 \u00b5g RBD + 20 \u00b5g EMV / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.Group 2 (experimental) FINLAY-FR-2: 25 \u00b5g of RBD-TT / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Injections; Intramuscular;SOBERANA&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 1 (experimental) FINLAY-FR-1: 50 \u00b5g RBD + 20 \u00b5g EMV / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 2 (experimental) FINLAY-FR-2: 25 \u00b5g of RBD-TT / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Injections; Intramuscular;SOBERANA&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 514, &quot;treatment_name&quot;: &quot;Finlay-fr-1 anti-sars-cov-2 vaccine&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 515, &quot;treatment_name&quot;: &quot;Finlay-fr-2 anti-sars-cov-2 vaccine&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;no third arm&quot;, &quot;treatment_id&quot;: 515, &quot;treatment_name&quot;: &quot;Finlay-fr-2 anti-sars-cov-2 vaccine&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="414301" class="table-">
                
                <td>June 17, 2022, 12:30 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Injections; Intramuscular;SOBERANA;Group 1 (experimental) FINLAY-FR-1: 50 \u00b5g RBD + 20 \u00b5g EMV / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.Group 2 (experimental) FINLAY-FR-2: 25 \u00b5g of RBD-TT / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 1 (experimental) FINLAY-FR-1: 50 \u00b5g RBD + 20 \u00b5g EMV / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 2 (experimental) FINLAY-FR-2: 25 \u00b5g of RBD-TT / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 514, &quot;treatment_name&quot;: &quot;Finlay-fr-1 anti-sars-cov-2 vaccine&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 515, &quot;treatment_name&quot;: &quot;Finlay-fr-2 anti-sars-cov-2 vaccine&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;no third arm&quot;, &quot;treatment_id&quot;: 2188, &quot;treatment_name&quot;: &quot;Standard of care&quot;, &quot;treatment_type&quot;: &quot;Standard of care&quot;, &quot;pharmacological_treatment&quot;: &quot;Standard of care&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="296105" class="table-">
                
                <td>March 17, 2022, 5 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 1 (experimental) FINLAY-FR-1: 50 \u00b5g RBD + 20 \u00b5g EMV / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.Group 2 (experimental) FINLAY-FR-2: 25 \u00b5g of RBD-TT / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Injections; Intramuscular;SOBERANA&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 1 (experimental) FINLAY-FR-1: 50 \u00b5g RBD + 20 \u00b5g EMV / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 2 (experimental) FINLAY-FR-2: 25 \u00b5g of RBD-TT / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Injections; Intramuscular;SOBERANA&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 514, &quot;treatment_name&quot;: &quot;Finlay-fr-1 anti-sars-cov-2 vaccine&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 515, &quot;treatment_name&quot;: &quot;Finlay-fr-2 anti-sars-cov-2 vaccine&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="295889" class="table-">
                
                <td>March 11, 2022, 3:30 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Injections; Intramuscular;SOBERANA;Group 1 (experimental) FINLAY-FR-1: 50 \u00b5g RBD + 20 \u00b5g EMV / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.Group 2 (experimental) FINLAY-FR-2: 25 \u00b5g of RBD-TT / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 1 (experimental) FINLAY-FR-1: 50 \u00b5g RBD + 20 \u00b5g EMV / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 2 (experimental) FINLAY-FR-2: 25 \u00b5g of RBD-TT / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;Finlay FR 1 50 \u00b5g RBD + 20 \u00b5g EMV / alumina + FINLAY-FR-1A: 50 \u00b5g dRBD / alumina;2+1;days0-28+day56;IM&quot;, &quot;treatment_id&quot;: 1978, &quot;treatment_name&quot;: &quot;Finlay-fr-1a anti-sars-cov-2 vaccine+finlay-fr-1 anti-sars-cov-2 vaccine&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;Finlay FR 2 25 \u00b5g RBD + 20 \u00b5g EMV / alumina + FINLAY-FR-1A: 50 \u00b5g dRBD / alumina;2+1;days0-28+day56;IM&quot;, &quot;treatment_id&quot;: 1519, &quot;treatment_name&quot;: &quot;Finlay-fr-1a anti-sars-cov-2 vaccine+finlay-fr-2 anti-sars-cov-2 vaccine&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="258478" class="table-">
                
                <td>Sept. 1, 2021, 11 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 1 (experimental) FINLAY-FR-1: 50 \u00b5g RBD + 20 \u00b5g EMV / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.Group 2 (experimental) FINLAY-FR-2: 25 \u00b5g of RBD-TT / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Injections; Intramuscular;SOBERANA&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 1 (experimental) FINLAY-FR-1: 50 \u00b5g RBD + 20 \u00b5g EMV / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 2 (experimental) FINLAY-FR-2: 25 \u00b5g of RBD-TT / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Injections; Intramuscular;SOBERANA&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

                </td>
            </tr>
            
        </tbody>
    </table>
</div>
Created at	Source	Raw Value	Validated value
July 7, 2022, 1:30 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Injections; Intramuscular;SOBERANA;Group 1 (experimental) FINLAY-FR-1: 50 \u00b5g RBD + 20 \u00b5g EMV / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.Group 2 (experimental) FINLAY-FR-2: 25 \u00b5g of RBD-TT / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 (experimental) FINLAY-FR-1: 50 \u00b5g RBD + 20 \u00b5g EMV / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 2 (experimental) FINLAY-FR-2: 25 \u00b5g of RBD-TT / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "50 \u00b5g, 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g ", "treatment_id": 514, "treatment_name": "Finlay-fr-1 anti-sars-cov-2 vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "25 \u00b5g; 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g", "treatment_id": 515, "treatment_name": "Finlay-fr-2 anti-sars-cov-2 vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]
June 23, 2022, 2 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 (experimental) FINLAY-FR-1: 50 \u00b5g RBD + 20 \u00b5g EMV / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.Group 2 (experimental) FINLAY-FR-2: 25 \u00b5g of RBD-TT / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Injections; Intramuscular;SOBERANA", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 (experimental) FINLAY-FR-1: 50 \u00b5g RBD + 20 \u00b5g EMV / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 2 (experimental) FINLAY-FR-2: 25 \u00b5g of RBD-TT / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Injections; Intramuscular;SOBERANA", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "", "treatment_id": 514, "treatment_name": "Finlay-fr-1 anti-sars-cov-2 vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 515, "treatment_name": "Finlay-fr-2 anti-sars-cov-2 vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "no third arm", "treatment_id": 515, "treatment_name": "Finlay-fr-2 anti-sars-cov-2 vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]
June 17, 2022, 12:30 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Injections; Intramuscular;SOBERANA;Group 1 (experimental) FINLAY-FR-1: 50 \u00b5g RBD + 20 \u00b5g EMV / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.Group 2 (experimental) FINLAY-FR-2: 25 \u00b5g of RBD-TT / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 (experimental) FINLAY-FR-1: 50 \u00b5g RBD + 20 \u00b5g EMV / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 2 (experimental) FINLAY-FR-2: 25 \u00b5g of RBD-TT / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "", "treatment_id": 514, "treatment_name": "Finlay-fr-1 anti-sars-cov-2 vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 515, "treatment_name": "Finlay-fr-2 anti-sars-cov-2 vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "no third arm", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]
March 17, 2022, 5 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 (experimental) FINLAY-FR-1: 50 \u00b5g RBD + 20 \u00b5g EMV / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.Group 2 (experimental) FINLAY-FR-2: 25 \u00b5g of RBD-TT / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Injections; Intramuscular;SOBERANA", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 (experimental) FINLAY-FR-1: 50 \u00b5g RBD + 20 \u00b5g EMV / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 2 (experimental) FINLAY-FR-2: 25 \u00b5g of RBD-TT / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Injections; Intramuscular;SOBERANA", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "", "treatment_id": 514, "treatment_name": "Finlay-fr-1 anti-sars-cov-2 vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 515, "treatment_name": "Finlay-fr-2 anti-sars-cov-2 vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]
March 11, 2022, 3:30 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Injections; Intramuscular;SOBERANA;Group 1 (experimental) FINLAY-FR-1: 50 \u00b5g RBD + 20 \u00b5g EMV / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.Group 2 (experimental) FINLAY-FR-2: 25 \u00b5g of RBD-TT / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 (experimental) FINLAY-FR-1: 50 \u00b5g RBD + 20 \u00b5g EMV / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 2 (experimental) FINLAY-FR-2: 25 \u00b5g of RBD-TT / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "Finlay FR 1 50 \u00b5g RBD + 20 \u00b5g EMV / alumina + FINLAY-FR-1A: 50 \u00b5g dRBD / alumina;2+1;days0-28+day56;IM", "treatment_id": 1978, "treatment_name": "Finlay-fr-1a anti-sars-cov-2 vaccine+finlay-fr-1 anti-sars-cov-2 vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Finlay FR 2 25 \u00b5g RBD + 20 \u00b5g EMV / alumina + FINLAY-FR-1A: 50 \u00b5g dRBD / alumina;2+1;days0-28+day56;IM", "treatment_id": 1519, "treatment_name": "Finlay-fr-1a anti-sars-cov-2 vaccine+finlay-fr-2 anti-sars-cov-2 vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]
Sept. 1, 2021, 11 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 (experimental) FINLAY-FR-1: 50 \u00b5g RBD + 20 \u00b5g EMV / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.Group 2 (experimental) FINLAY-FR-2: 25 \u00b5g of RBD-TT / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Injections; Intramuscular;SOBERANA", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 (experimental) FINLAY-FR-1: 50 \u00b5g RBD + 20 \u00b5g EMV / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 2 (experimental) FINLAY-FR-2: 25 \u00b5g of RBD-TT / alumina; 0.5 mL; Intramuscular (IM); 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 \u00b5g dRBD / alumina; 0.5 mL; Intramuscular (IM). Presentation: Vial with single dose.;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Injections; Intramuscular;SOBERANA", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]